ClinicalTrials.gg
CompletedNCT04472832Updated Feb 18, 2021

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

A Phase 1 interventional study of Placebo for Treatment A and Mitapivat 100 mg in Healthy Volunteers, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, randomized, single-dose, double-blinded, 4-period, crossover study to evaluate the pharmacokinetics, safety, and tolerability of mitapivat in healthy adult participants under fasted and fed (high-fat meal) conditions. Secondary objectives include evaluating the effect of mitapivat on electrocardiogram (ECG) parameters, including concentration-QT interval corrected for heart rate (C-QTc) analysis under fasted conditions. The study will include a 28-day screening period, four 7-day treatment periods. Participants will receive a follow-up telephone call within 28 (±1) days after the last dose of study drug.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is male or female 18 to 55 years of age, inclusive;
  • If female, is not currently pregnant or breastfeeding OR is of non-, defined as either:

    • Being clinically infertile as the result of surgical sterilization, confirmed status, or another documented medical condition (eg, was born without a uterus) OR
    • Agreeing to either abstain from sexual intercourse with a male partner OR agrees to use a highly effective form of , beginning at the time of screening and continuing throughout the study and for 28 days after dosing. The following are considered highly effective forms of contraception: hormonal oral contraceptives, injectables, and patches; intrauterine devices; double-barrier methods (synthetic condom, diaphragm, or cervical cap used with spermicidal foam, cream, or gel); and male partner sterilization;
  • If male, agrees to abstain from sexual intercourse with a female partner OR agrees to use a highly effective form of contraception, beginning at the time of screening and continuing throughout the study and for 90 days after dosing, AND to refrain from donating sperm for the duration of the study and for 90 days after dosing;
  • Participant has a 18 to 32 kilograms per square meter (kg/m\^2), inclusive, at screening;
  • Participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at screening;
  • Participant has no history or presence of ECG findings as judged by the investigator at screening and check-in, including each criterion as follows:

    • Normal sinus rhythm (heart rate [HR] between 45 beats per minute [bpm] and 100 bpm inclusive);
    • corrected for HR using Fridericia's formula (QTcF) ≤450 milliseconds (msec);
    • QRS interval ≤110 msec; and confirmed by manual over read if >110 msec;
    • PR interval between 120 and 220 msec;
  • Participant agrees to comply with all protocol requirements;
  • Participant is able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Participant has any medical or surgical condition that, in the opinion of the investigator, could affect study drug absorption, distribution, metabolism, or excretion;
  • Participant has undergone any major surgical procedure within the 3 months prior to screening;
  • Participant has a history of any primary (including any melanoma or suspicious undiagnosed skin lesions), with the exception of in situ basal cell or squamous cell carcinomas of the skin, cervical carcinoma in situ, or other malignancies that have been curatively treated and for which the participant has displayed no evidence of disease within the 5 years prior to screening;
  • Participant has glucose-6-phosphate-dehydrogenase deficiency;
  • Participant has a known history or presence of liver disease.
  • Participant has a positive test result for surface antigen (HBsAg), virus antibody (HCVAb), or (HIV) types 1 or 2 antibodies at screening;
  • Participant has liver function tests including (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total that are greater than the at screening or check-in (results may be repeated once);
  • Participant has count or and hematocrit values that are below the lower limit of normal at screening or check-in (results may be repeated once);
  • Participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at screening or before the first dose of study drug or throughout the study.
  • Participant has used any prescription (excluding hormonal ) medications within 30 days (or 5 half-lives, whichever is longer) before the first dose of study drug or throughout the study;
  • Participant has used any over-the-counter medications, including herbal or nutritional supplements, within 28 days (or 5 half-lives, whichever is longer) before the first dose of study drug or throughout the study;
  • Participant has received study drug in another study within 30 days (or 5 half-lives, whichever is longer) of dosing.
  • Participant has donated blood or blood products >450 milliliters (mL) within 30 days before the first dose of study drug.
  • Participant has history or presence of:

    • Risk factors for torsades de pointes (eg, heart failure, cardiomyopathy, or family history of long syndrome);
    • Sick sinus syndrome, second- or third-degree atrioventricular block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or conduction abnormalities;
    • Repeated or frequent syncope or vasovagal episodes;
    • Hypertension, angina, bradycardia (if assessed as by the investigator), or severe peripheral arterial circulatory disorders;
    • Clinically significant laboratory assessment findings, including hypokalemia, hypercalcemia, or hypomagnesemia;
  • Participant has history or presence of:

    • Any evidence of atrial fibrillation, atrial flutter, complete right or left bundle branch block, or Wolff-Parkinson-White syndrome on the screening or baseline ;
    • Any morphology that renders measurement of QT interval imprecise (eg, neuromuscular artifact that cannot be readily eliminated, indistinct QRS onset, low-amplitude T-wave, merged T and U-waves, prominent U-waves, arrhythmia) on the screening or baseline ECG.
  • Participant is not willing to refrain from marijuana or cannabinol-containing products for 7 days before the first dose of study drug and throughout the study;
  • Participant has consumed caffeine- or xanthine containing products within 24 hours prior to first dose of study drug or throughout the study;
  • Participant has consumed grapefruit or grapefruit juice, Seville orange or Seville orange containing products (eg, marmalade) within 28 days before the first dose of study drug or throughout the study;
  • Participant has consumed fruit juices 72 hours prior to first dosing or during the study (with exception to the juices in relation to the fruits specified above);
  • Participant has consumed vegetables from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussel sprouts, and mustard), or charbroiled meats for 7 days prior to first dose of study drug or throughout the study;
  • Participant is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, vaporizers, or inhalers) within 6 months before the first dose of study drug;
  • Participant has a history of alcohol abuse or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake >21 units per week for male participants and >14 units of alcohol per week for female participants) (1 unit is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits) or consumed alcohol 72 hours before the first dose of study drug or throughout the follow-up telephone call;
  • Participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug or throughout the study;
  • Participant has a history of relevant drug and/or food allergies (ie, allergy to mitapivat or [microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, magnesium stearate, and mannitol]);
  • Participant has a history of allergy to sulfonamides (eg, co-trimoxazole antibiotic, silver sulfadiazine topical antibiotic for burn wounds) that has been characterized by acute hemolytic anemia, drug-induced liver injury, anaphylaxis, rash of erythema multiforme type, or Stevens-Johnson syndrome;
  • In the opinion of the investigator, the participant is not suitable for entry into the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Placebo comparator
    Treatment A

    Participants will receive a single oral dose of mitapivat-matching placebo under fasted conditions on Day 1 of each of 4 periods.

    Drug: Placebo for Treatment A

  • Experimental
    Treatment B

    Participants will receive a single oral dose of mitapivat 100 milligrams (mg) and placebo under fasted conditions on Day 1 of each of 4 periods.

    Drug: Mitapivat 100 mg · Drug: Placebo for Treatment B

  • Experimental
    Treatment C

    Participants will receive a single oral dose of mitapivat 100 mg and placebo under high-fat meal conditions on Day 1 of each of 4 periods.

    Drug: Mitapivat 100 mg · Drug: Placebo for Treatment C

  • Experimental
    Treatment D

    Participants will receive a single oral dose of mitapivat 300 mg under fasted conditions on Day 1 of each of 4 periods.

    Drug: Mitapivat 300 mg

Interventions

  • DrugPlacebo for Treatment A

    6 tablets matched to mitapivat tablet

  • Two 50-mg tablets

    Also known as: AG-348

  • DrugPlacebo for Treatment B

    4 tablets matched to mitapivat tablet

  • Six 50-mg tablets

    Also known as: AG-348

  • DrugPlacebo for Treatment C

    4 tablets matched to mitapivat tablet

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Last Quantifiable Concentration (AUC0-T) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  2. AUC From Time 0 Extrapolated to Infinity (AUC0-Inf) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  3. Maximum Observed Plasma Concentration (Cmax) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  5. Apparent Terminal Elimination Half-Life (T1/2) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  6. Apparent Oral Clearance (CL/F) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  7. Apparent Terminal Elimination Rate Constant (Λz) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  8. Apparent Volume of Distribution (Vd/F) for Mitapivat Under Fasted and High-Fat Meal Conditions

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

  9. Relative Bioavailability (Frel; AUC0-Inf [fed]/AUC0-Inf [fasted]) for Fed Treatment Following Administration of Mitapivat 100-mg Dose

    Time frame: Predose and at various timepoints through 120 hours postdose within each 7-day period

Secondary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug.

    Time frame: Up to approximately 8 weeks

  2. Percentage of Participants with Abnormalities in Clinical Laboratory Findings

    Clinical laboratory tests will include hematology, serum chemistry, and urinalysis.

    Time frame: Up to approximately 8 weeks

  3. Percentage of Participants With Abnormalities in Vital Sign Measurements

    Vital sign measurements will include systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature.

    Time frame: Up to approximately 8 weeks

  4. Percentage of Participants With Abnormalities in 12-lead Electrocardiogram (ECG) Results

    Time frame: Up to approximately 8 weeks

  5. Percentage of Participants With Abnormalities in Physical Examination Findings

    Time frame: Up to approximately 8 weeks

07

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Nov 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 15, 2020
StartActual
Jun 17, 2020
Primary completionActual
Nov 23, 2020
CompletionActual
Nov 23, 2020
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04472832
Responsible party
Sponsor
First posted
Jul 15, 2020
Start date
Jun 17, 2020
Primary completion
Nov 23, 2020
Completion
Nov 23, 2020
Last update
Feb 18, 2021

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion